You are here

Daiichi Sankyo

Daiichi exits combo vaccine pact with Sanofi after pertussis shot manufacturing glitches

Daiichi exits combo vaccine pact with Sanofi after pertussis shot manufacturing glitches

Fierce Pharma

drug manufacturing

Flag link:

Daiichi takes mRNA COVID-19 vaccine into clinic as Japanese R&D belatedly fires up

Daiichi takes mRNA COVID-19 vaccine into clinic as Japanese R&D belatedly fires up

Fierce Biotech

Flag link:

AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication

AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication

Pharmaforum

Flag link:

Sanofi inks COVID-19 mRNA vaccine deal with Translate BioDaiichi Sankyo’s Mirogabalin Displays Significant Reduction in Post-SCI Neuropathic Pain

Sanofi inks COVID-19 mRNA vaccine deal with Translate BioDaiichi Sankyo’s Mirogabalin Displays Significant Reduction in Post-SCI Neuropathic Pain

BioSpace

central neuropathic pain after spinal cord injury

spinal cord injury

Flag link:

Daiichi Sankyo takes oncology shift into next phase with new global business unit

Daiichi Sankyo takes oncology shift into next phase with new global business unit

Fierce Pharma

Flag link:

Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer

Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer

Endpoints

breakthrough status

metastatic gastric cancer

Flag link:

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

Pharmaceutical Business Review

patritumab deruxtecan

non-small cell lung cancer

clinical trials

Flag link:

4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront

4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront

Motley Fool

Flag link:

AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

Pharmaforum

Flag link:

Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer

Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer

Pharmaceutical Business Review

antibody-drug conjugate

triple negative breast cancer

clinical trials

Flag link:

AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful

AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful

Fierce Pharma

University of Oxford

Flag link:

Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC

Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC

BioSpace

companion diagnostics

non-small cell lung cancer

Flag link:

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

Pharmaforum

colorectal cancer

Flag link:

AZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a week

AZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a week

Pharmaforum

metastatic non-small-cell lung cancer

Flag link:

AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug

AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug

Pharmaceutical Business Review

breakthrough therapy

Flag link:

Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan

Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan

Pharmaceutical Business Review

axicabtagene ciloleucel

relapsed or refractory diffuse large B-cell lymphoma

Flag link:

Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer

Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer

Fierce Biotech

clinical trials

HER2-positive non-small cell lung cancer

Flag link:

AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch

AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch

Fierce Pharma

clinical trials

Flag link:

Antibody-drug conjugates on the march

Antibody-drug conjugates on the march

Pharmaforum

antibody-drug conjugate

Flag link:

Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study

Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study

Endpoints

trastuzumab deruxtecan

Flag link:

Pages